Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 6/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 3/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6956458 | 0.80 | MGLL (0.40) | MGLLCYP1A2CYP2D6FAAH | |
| SCHEMBL5661272 | 0.78 | MGLL (0.42) | MGLLCYP1A2CYP2D6FAAHTDP1 | |
| SCHEMBL5661991 | 0.78 | MGLL (0.42) | MGLLCYP1A2CYP2D6FAAHTDP1 | |
| SCHEMBL5663686 | 0.78 | MGLL (0.42) | MGLLCYP1A2CYP2D6FAAHTDP1 | |
| SCHEMBL5662288 | 0.77 | ADRA1A (0.42) | MGLLCYP1A2CYP2D6FAAH | |
| SCHEMBL8174001 | 0.77 | ADRA1A (0.42) | MGLLCYP1A2CYP2D6FAAH | |
| SCHEMBL5658840 | 0.77 | ADRA1A (0.42) | MGLLCYP1A2CYP2D6FAAH | |
| SCHEMBL7966161 | 0.77 | MGLL (0.43) | MGLLCYP1A2CYP2D6FAAH | |
| SCHEMBL8173301 | 0.77 | MGLL (0.43) | MGLLCYP1A2CYP2D6FAAH | |
| SCHEMBL6222781 | 0.76 | MGLL (0.38) | MGLLCYP1A2CYP2D6FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6620815-B1 | Selective antagonists for human alpha 1A receptors; benign prostatic hyperplasia, impotency, cardiac arrhythmia treatment; anticholesterol agents; intraocular pressure reduction | SYNAPTIC PHARMACEUTICAL CORPORATION | 2003-09-16 | — | — | US | disclosed |
| EP-0988295-A4 | HETEROCYCLIC SUBSTITUTED PIPERIDINES AND USES THEREOF | SYNAPTIC PHARMA CORP (US) | 2003-08-13 | — | — | EP | disclosed |
| US-6159990-A | Oxazolidinones as α1A receptor antagonists | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2000-12-12 | — | — | US | disclosed |
| EP-0988295-A1 | HETEROCYCLIC SUBSTITUTED PIPERIDINES AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2000-03-29 | — | — | EP | disclosed |
| WO-1998057940-A1 | HETEROCYCLIC SUBSTITUTED PIPERIDINES AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1998-12-23 | — | — | WO | disclosed |